BTIG analyst Mark Massaro raised the firm’s price target on Caris Life Sciences (CAI) to $45 from $38 and keeps a Buy rating on the shares. The company reported a nearly unprecedented 31% revenue beat in its first quarter as a public company, driven primarily by higher-than-expected mix contribution from its MI Cancer Seek CDx, which carries a premium CMS rate of $8,455, the analyst tells investors in a research note. Caris seems to be holding firmly onto its market leadership in tissue therapy selection and estimates that the therapy selection market stands at just 30% overall penetration, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences price target raised to $42 from $34 at Citi
- Caris Life Sciences Reports Strong Q2 2025 Results
- Strong Performance and Growth Potential: Caris Life Sciences, Inc. Receives Buy Rating with Increased Price Target
- Closing Bell Movers: CoreWeave down 10% despite revenue beat, guidance raise
- Caris Life Sciences reports Q2 EPS ($7.97) with items, consensus (22c)